

Performance Report

The Queenstown Molecular Biology Meeting Incorporated
For the year ended 31 March 2025

Prepared by Monteck Carter LP

Contents

3	Compilation Report
4	Entity Information
5	Approval of Financial Report
6	Statement of Financial Performance
7	Statement of Financial Position
8	Statement of Cash Flows
9	Statement of Accounting Policies
10	Notes to the Performance Report

Compilation Report

The Queenstown Molecular Biology Meeting Incorporated For the year ended 31 March 2025

Compilation Report to the Governing Body of The Queenstown Molecular Biology Meeting Incorporated.

Scope

On the basis of information provided and in accordance with Service Engagement Standard 2 Compilation of Financial Information, we have compiled the financial statements of The Queenstown Molecular Biology Meeting Incorporated for the year ended 31 March 2025.

These statements have been prepared in accordance with the accounting policies described in the Notes to these financial statements.

Responsibilities

The Governing Body are solely responsible for the information contained in this financial report and have determined that the accounting policies used are appropriate to meet your needs and for the purpose that the financial statements were prepared.

The financial statements were prepared exclusively for your benefit. We do not accept responsibility to any other person for the contents of the financial statements.

No Audit or Review Engagement Undertaken

Our procedures use accounting expertise to undertake the compilation of the financial statements from information you provided. Our procedures do not include verification or validation procedures. No audit or review engagement has been performed and accordingly no assurance is expressed.

Independence

We have no involvement with The Queenstown Molecular Biology Meeting Incorporated other than for the preparation of financial statements and management reports and offering advice based on the financial information provided.

Disclaimer

We have compiled these financial statements based on information provided which has not been subject to an audit or review engagement. Accordingly, we do not accept any responsibility for the reliability, accuracy or completeness of the compiled financial information contained in the financial statements. Nor do we accept any liability of any kind whatsoever, including liability by reason of negligence, to any person for losses incurred as a result of placing reliance on this financial report.

Monteck Carter

Monteck Carter Limited Partnership

Auckland

Dated: 10 August 2025

Entity Information

The Queenstown Molecular Biology Meeting Incorporated For the year ended 31 March 2025

Purpose

The Queenstown Molecular Biology Meeting Incorporated exists for the purpose of organising and convening the Annual Molecular Biology conference during Queenstown Research Week

Legal Name of Entity

The Queenstown Molecular Biology Meeting Incorporated

Entity Type and Legal Basis

Incorporated Society governed by the Incorporated Societies Act 1908

Registration Number

636966 (NZBN: 9429042869078)

IRD Number: 064-300-792

Governing Body

Dr Rachel Purcell (Chairperson)

Dr. Hilary (Billy) Sheppard (Treasurer)

Dr. Bjorn Oback

Entity's Purpose or Mission

Education and Medical Research

Main Sources of Entity's Cash and Resources

Sponsorship

Entity's Governance Arrangements

The entity is governed by a committee with a specialisation in molecular biology. The committee is appointed by vote at the annual general meeting. Committee members can be co-opted by the committee during the year to achieve a quorum.

Approval of Financial Report

The Queenstown Molecular Biology Meeting Incorporated For the year ended 31 March 2025

The Committee are pleased to present the approved financial report including the historical financial statements of The Queenstown Molecular Biology Meeting Incorporated for year ended 31 March 2025.


APPROVED



Dr. Rachel Purcell

Chairperson

Date



Dr. Hilary (Billy) Sheppard

Treasurer

Date

Statement of Financial Performance

The Queenstown Molecular Biology Meeting Incorporated For the year ended 31 March 2025

	NOTES	2025	2024
Revenue			
Revenue from providing goods or services	1	273,705	127,781
Interest, dividends and other investment revenue	1	4,570	7,801
Other revenue	1	17,835	-
Total Revenue		296,110	135,583
Expenses			
Costs related to providing goods or services	2	333,273	187,649
Grants and donations made	2	400	-
Other expenses	2	5,500	500
Total Expenses		339,173	188,149
Surplus/(Deficit) for the Year		(43,063)	(52,566)

This statement has been prepared without conducting an audit or review engagement, and should be read in conjunction with the attached Compilation Report.

Statement of Financial Position

The Queenstown Molecular Biology Meeting Incorporated As at 31 March 2025

	NOTES	31 MAR 2025	31 MAR 2024
Assets			
Current Assets			
Bank accounts and cash	3	132,502	259,808
Debtors and prepayments	3	87,322	87,636
Total Current Assets		219,823	347,443
Total Assets		219,823	347,443
Liabilities			
Current Liabilities			
Goods and services tax		(2,831)	13,339
Net unearned conference sponsorship and prepaid expenses	6	(8,949)	59,439
Creditors and accrued expenses	4	613	613
Total Current Liabilities		(11,167)	73,391
Total Liabilities		(11,167)	73,391
Total Assets less Total Liabilities (Net Assets)		230,990	274,053
Accumulated Funds			
Accumulated surpluses or (deficits)	5	230,990	274,053
Total Accumulated Funds		230,990	274,053

This statement has been prepared without conducting an audit or review engagement, and should be read in conjunction with the attached Compilation Report.

Statement of Cash Flows

The Queenstown Molecular Biology Meeting Incorporated For the year ended 31 March 2025

	2025	2024
Cash Flows from Operating Activities		
Receipts from providing goods or services	333,455	246,963
Interest, dividends and other investment receipts	4,570	5,070
Cash receipts from other operating activities	20,510	-
GST	14,447	72,611
Payments related to commercial activities	(499,888)	(337,783)
Donations or grants paid	(400)	-
Total Cash Flows from Operating Activities	(127,306)	(13,138)
Cash Flows from Investing and Financing Activities		
Cash flows from other investing and financing activities		
Rounding	-	-
Total Cash Flows from Investing and Financing Activities	-	-
Net Increase/(Decrease) in Cash	(127,306)	(13,138)
Bank Accounts and Cash		
Opening cash	259,808	272,946
Net change in cash for period	(127,306)	(13,138)
Closing cash	132,502	259,808

This statement has been prepared without conducting an audit or review engagement, and should be read in conjunction with the attached Compilation Report.

Statement of Accounting Policies

The Queenstown Molecular Biology Meeting Incorporated For the year ended 31 March 2025

Basis of Preparation

The Queenstown Molecular Biology Meeting is permitted by law to apply prepare financial statements under the Incorporated Societies Act 1908. All transactions in the Performance Report are reported using the accrual basis of accounting. The Performance Report is prepared under the assumption that the entity will continue to operate in the foreseeable future.

Goods and Services Tax (GST)

The entity is registered for GST. All amounts are stated exclusive of goods and services tax (GST) except for accounts payable and accounts receivable which are stated inclusive of GST. The entity has adopted payments basis for GST purposes.

Income Tax

The Queenstown Molecular Biology Meeting Incorporated is wholly exempt from New Zealand income tax having fully complied with all statutory conditions for these exemptions.

Bank Accounts and Cash

Bank accounts and cash in the Statement of Cash Flows comprise cash balances and bank balances.

Changes in Accounting Policies

There have been no changes in accounting policies. Policies have been applied on a consistent basis with those of the previous reporting period.

Notes to the Performance Report

The Queenstown Molecular Biology Meeting Incorporated For the year ended 31 March 2025

	2025	2024
1. Analysis of Revenue		
Revenue from providing goods or services		
Sponsorship	273,705	127,781
Total Revenue from providing goods or services	273,705	127,781
Interest, dividends and other investment revenue		
Interest Received	4,570	7,801
Total Interest, dividends and other investment revenue	4,570	7,801
Other revenue		
Sundry Income	17,835	-
Total Other revenue	17,835	-

	2025	2024
2. Analysis of Expenses		
Costs related to providing goods or services		
Bank Charges	192	125
Computer and Website Expenses	1,271	732
Conference Expenses - General	-	2,000
Conference Management Fee and Direct Venue Costs	331,927	184,742
General Expenses	(117)	-
IRD Penalties	-	50
Total Costs related to providing goods or services	333,273	187,649
Grants and donations made		
Donations	400	-
Total Grants and donations made	400	-
Other expenses		
Accountancy Fees	5,500	500
Total Other expenses	5,500	500

	2025	2024
3. Analysis of Assets		
Bank accounts and cash		
Business Premium Current Account 00	120,483	212,134
Business Premium Current Account 02	11,654	947
Business Premium Online Account 03	85	3,257
Business Premium Call Account 06	280	274
ANZ Term Deposit 1000	-	43,195
Total Bank accounts and cash	132,502	259,808

	2025	2024
Debtors and prepayments		
Accounts Receivable (Xero)	87,322	87,636
Total Debtors and prepayments	87,322	87,636

	2025	2024
--	------	------

4. Analysis of Liabilities

Creditors and accrued expenses		
Accounts Payable (Xero)	613	613
Conference Income and Expenditure in Advance (Note 6)	(8,949)	59,439
GST	(2,831)	13,339
Total Creditors and accrued expenses	(11,167)	73,391

Other current liabilities		
Rounding	-	-
Total Other current liabilities	-	-

	2025	2024
--	------	------

5. Accumulated Funds

Accumulated Funds		
Opening Balance	274,053	326,619
Accumulated surpluses or (deficits)	(43,063)	(52,566)
Total Accumulated Funds	230,990	274,053
Total Accumulated Funds	230,990	274,053

Contingent Liabilities and Guarantees

There are no contingent liabilities or guarantees as at 31 March 2024 Last year - nil).

	2025	2024
--	------	------

6. Conference Income and Expenditure in Advance for Conference Dated Sept 24

Deferred Sponsorship Income	193,410	-
Deferred Conference Expense	(202,359)	-
Total Conference Income and Expenditure in Advance for Conference Dated Sept 24	(8,949)	-

Related Parties

There were no transactions involving related parties during the financial year.

7. Ability to Continue Operating

The entity will continue to operate for the foreseeable future.